Thinly traded nano cap Aytu BioScience (NASDAQ:AYTU) is up 9% premarket on light volume in reaction to its announcement that an unnamed "leading" pharmacy benefit manager (PBM) has added Natesto (testosterone nasal gel) to its formulary.
The company says 30M American lives are covered by prescription plans administered by the PBM.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.